NCODA Logo

Ponatinib (Iclusig®) Patient Management

Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital DOWNLAD HERE Description: This PQI will aim to review ponatinib efficacy and safety data as well as clinical pearls regarding supportive care and adverse event management.1 Background:...

Managing EGFR Inhibitor Induced Rash

Written by: Sara Moran Smith, PharmD, BCOP | M Health Fairview DOWNLOAD HERE Purpose: Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR)  inhibitors1 with 10-20% developing severe eruption.1 Studies have shown that the...

DPYD Testing Prior to Fluoropyrimidine Treatment

Written by: Dan Hertz, PharmD, PhD – University of Michigan College of Pharmacy DOWNLOAD HERE Description: The purpose of this PQI is to review recommendations for DPYD testing prior to initiation of treatment with fluoropyrimidine based chemotherapy and...